Search

Your search keyword '"Costa, Priscilla Ramos"' showing total 11 results
Start Over Author "Costa, Priscilla Ramos"
11 results on '"Costa, Priscilla Ramos"'

2. Expression of TIGIT, PD-1 and HLA-DR/CD38 markers on CD8-T cells of children and adolescents infected with HIV and uninfected controls

Author

Pereira-Manfro, Wânia Ferraz, primary, Silva, Giselle Pereira da, additional, Costa, Priscilla Ramos, additional, Costa, Dayane Alves, additional, Ferreira, Bianca da Silva, additional, Barreto, Daniela Mena, additional, Frota, Ana Cristina Cisne, additional, Hofer, Cristina Barroso, additional, Kallas, Esper Georges, additional, and Milagres, Lucimar Gonçalves, additional

Published
2023
Full Text
View/download PDF

3. Humoral and cellular immune responses to CoronaVac up to one year after vaccination

Author

Costa, Priscilla Ramos, primary, Correia, Carolina Argondizo, additional, Marmorato, Mariana Prado, additional, Dias, Juliana Zanatta de Carvalho, additional, Thomazella, Mateus Vailant, additional, Cabral da Silva, Amanda, additional, de Oliveira, Ana Carolina Soares, additional, Gusmão, Arianne Fagotti, additional, Ferrari, Lilian, additional, Freitas, Angela Carvalho, additional, Patiño, Elizabeth González, additional, Grifoni, Alba, additional, Weiskopf, Daniela, additional, Sette, Alessandro, additional, Scharf, Rami, additional, Kallás, Esper Georges, additional, and Silveira, Cássia Gisele Terrassani, additional

Published
2022
Full Text
View/download PDF

5. Immunophenotypical Characterization of a Brazilian POIS (Post-Orgasmic Illness Syndrome) Patient: Adding More Pieces to Puzzle.

Author

De Amicis, Karine, Costa, Priscilla Ramos, Figo, Daniele Danella, De Lima, Cynthia Mafra Fonsecade, Castro, Fabio Fernandes Morato, Kalil, Jorge, Santos, Keity Souza, and Galvão, Clovis Eduardo Santos

Subjects
*DISEASES, *SYNDROMES, *ETIOLOGY of diseases, *INVESTIGATIONS, *ALLERGIES
Abstract

Post-orgasmic illness syndrome (POIS) is a rare condition characterized by post-ejaculatory symptoms. Here is reported the first Brazilian POIS patient. Immunological investigation did not confirm the previous hypothesis of a hypersensitivity reaction. Cell immunophenotyping comparing healthy individuals produced evidence of abnormalities not associated to clinical manifestations. The patient was submitted to specific immunotherapy with transient clinical response and was referred to a psychologist but did not demonstrate clinical improvement of symptoms. Therefore, etiology of POIS remains unclear. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men

Author

Soares de Oliveira, Ana Carolina, primary, Pessôa de Farias, Rodrigo, additional, da Costa, Antonio Charlys, additional, Sauer, Mariana Melillo, additional, Bassichetto, Katia Cristina, additional, Oliveira, Solange Maria Santos, additional, Costa, Priscilla Ramos, additional, Tomiyama, Claudia, additional, Tomiyama, Helena Tomoko Iwashita, additional, Sabino, Ester Cerdeira, additional, Kallas, Esper Georges, additional, and Sanabani, Sabri Saeed, additional

Published
2012
Full Text
View/download PDF

9. Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men

Author

Sanabani, Sabri Saeed, primary, Soares de Oliveira, Ana Carolina, additional, da Costa, Antonio Charlys, additional, Melillo, Mariana, additional, Cristina Bassichetto Solange, Sauer Katia, additional, Oliveira, Maria Santos, additional, Costa, Priscilla Ramos, additional, Tomiyama, Claudia, additional, Tomiyama, Helena Tomoko Iwashita, additional, Cerdeira, Ester, additional, Esper, Sabino, additional, and Kal, Georges, additional

Published
2012
Full Text
View/download PDF

11. Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination.

Author

Costa PR, Correia CA, Marmorato MP, de Carvalho Dias JZ, Thomazella MV, da Silva AC, de Oliveira ACS, Gusmão AF, Ferrari L, Freitas AC, Patiño EG, Grifoni A, Weiskopf D, Sette A, Scharf R, Kallas EG, and Terrassani Silveira CG

Abstract

Background: The Sinovac SARS-CoV-2 inactivated vaccine (CoronaVac) has been demonstrated to be safe, well tolerated, and efficacious in preventing mild and severe Covid-19. Although different studies have demonstrated its short-term immunogenicity, long-term cellular and humoral response evaluations are still lacking., Methods: Cellular and humoral responses were assessed after enrollment of volunteers in the PROFISCOV phase 3 double-blind, randomized, placebo-controlled clinical trial to evaluate CoronaVac. Assays were performed using flow cytometry to evaluate cellular immune response and an antigen binding electrochemiluminescence assay to detect antigen-specific antibodies to the virus., Results: Fifty-three volunteers were selected for long term assessment of their SARS-CoV-2-specific immune responses. CD4 + T cell responses (including circulating follicular helper (cTfh, CD45RA - CXCR5 + ) expressing CD40L, as well as non-cTfh cells expressing CXCR3) were observed early upon the first vaccine dose, increased after the second dose, remaining stable for 6-months. Memory CD4 + T cells were detected in almost all vaccinees, the majority being central memory T cells. IgG levels against Wuhan/WH04/2020 N, S and receptor binding domain (RBD) antigens and the variants of concern (VOCs, including B.1.1.7/Alpha, B.1.351/Beta and P.1/Gamma) S and RBD antigens peaked 14 days after the second vaccine shot, and were mostly stable for a 1-year period., Conclusions: CoronaVac two-doses regimen is able to induce a potent and durable SARS-CoV-2 specific cellular response. The cellular reaction is part of a coordinated immune response that includes high levels of specific IgG levels against parental and SARS-CoV-2 VOC strains, still detected after one year., Funding: Fundação Butantan, Instituto Butantan and São Paulo Research Foundation (FAPESP) (grants 2020/10127-1 and 2020/06409-1). This work has also been supported by NIH contract 75N93019C00065 (A.S, D.W). PATH facilitated reagent donations for this work with support by the Bill & Melinda Gates Foundation (INV-021239). Under the grant conditions of the foundation, a Creative Commons Attribution 4.0 generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results